Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
20-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
20-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
14 May 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/adc-therapeutics-drops-last-clinical-stage-after-reviewing-phase-1-leukemia-data
14 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/adc-therapeutics-announces-presentation-of-lotis-7-clinical-trial-data-at-the-european-hematology-association-2025-congress-eha2025-and-the-18th-international-conference-on-malignant-lymphoma-icml-302454626.html
01 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302414722.html
30 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/adc-therapeutics-announces-completion-of-enrollment-of-phase-3-confirmatory-clinical-trial-of-zynlonta-in-combination-with-rituximab-in-2l-diffuse-large-b-cell-lymphoma-302338974.html
11 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/adc-therapeutics-announces-positive-initial-data-from-lotis-7-clinical-trial-evaluating-zynlonta-in-combination-with-bispecific-antibody-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-302328090.html
09 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/adc-therapeutics-announces-the-lancet-haematology-publication-of-data-from-investigator-initiated-trial-evaluating-zynlonta-in-combination-with-rituximab-to-treat-relapsedrefractory-follicular-lymphoma-302325360.html
ABOUT THIS PAGE
ADC Therapeutics is a supplier offers 4 products (APIs, Excipients or Intermediates).
Find a price of PL1601 DRUG LINKER bulk with DMF offered by ADC Therapeutics
Find a price of ADCT-701 DRUG PRODUCT bulk with DMF offered by ADC Therapeutics
Find a price of HUBA-1-3D-GAINACN3 MAB bulk with DMF offered by ADC Therapeutics
Find a price of ADCT-701 DRUG SUBSTANCE bulk with DMF offered by ADC Therapeutics